Cases & Deals

Stallergenes Greer plc acquired by Waypoint for approximately €110 million (US$124 million)

Clients Stallergenes Greer plc

Jones Day advised Stallergenes Greer plc in the recommended cash acquisition by Ares Life Sciences I S.à r.l. (Waypoint) of the entire issued, and to be issued, ordinary share capital of Stallergenes Greer not held directly or indirectly by Waypoint by way of a scheme of arrangement for approximately €110 million (US$124 million).

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.